Security
Tenaya Therapeutics, Inc. Common Stock · TNYA
TNYANASDAQCommon stockCurrentCIK 1858848Updated Oct 26, 2026
TNYA price & chart
Loading TradingView…
NASDAQ:TNYA on TradingView ↗About the company
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
In the news
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) ↗
Seeking Alpha
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript ↗
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript ↗
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript ↗
SEC disclosures
Tenaya Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 104,980,000Source | 140,582,000Source | 93,540,000Source | 122,151,000Source | 163,185,000Source | 135,070,000Source | 143,952,000Source | 184,899,000Source | 146,921,000Source | 119,940,000Source | 170,515,000Source | 278,945,000Source |
| Property, Plant and Equipment, NetUSD | 29,440,000Source | 37,753,000Source | 2,494,000Source | 31,285,000Source | 39,437,000Source | 25,960,000Source | 33,360,000Source | 41,396,000Source | 27,672,000Source | 35,858,000Source | 43,277,000Source | 51,032,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 56,312,000Source | 8,231,000Source | 78,085,000Source | 62,671,000Source | 58,134,000Source | 80,887,000Source | 53,772,000Source | 59,303,000Source | 100,547,000Source | 4,323,000Source | 45,681,000Source | 95,272,000Source |
| Assets, CurrentUSD | 61,239,000Source | 85,330,000Source | 86,008,000Source | 75,875,000Source | 105,029,000Source | 96,562,000Source | 94,485,000Source | 128,699,000Source | 105,586,000Source | 67,375,000Source | 111,582,000Source | 193,754,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,927,000Source | 5,861,000Source | 7,552,000Source | 4,208,000Source | 5,726,000Source | 5,048,000Source | 6,327,000Source | 6,450,000Source | 5,039,000Source | 5,929,000Source | 6,940,000Source | 7,227,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,057,000Source | 12,626,000Source | 2,966,000Source | 10,682,000Source | 13,656,000Source | 8,763,000Source | 11,294,000Source | 9,177,000Source | 9,417,000Source | 11,890,000Source | 9,979,000Source | 11,663,000Source |
| Other Assets, NoncurrentUSD | 4,244,000Source | 4,873,000Source | 2,072,000Source | 4,309,000Source | 5,063,000Source | 3,785,000Source | 4,813,000Source | 5,627,000Source | 4,246,000Source | 4,817,000Source | 5,677,000Source | 4,793,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 22,112,000Source | 27,980,000Source | 24,131,000Source | 22,323,000Source | 29,188,000Source | 28,881,000Source | 24,556,000Source | 26,719,000Source | 23,656,000Source | 27,086,000Source | 31,091,000Source | 35,569,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 16,000Source | 8,000Source | 22,000Source | 16,000Source | 8,000Source | 21,000Source | 16,000Source | 8,000Source | 21,000Source | 8,000Source | 7,000Source | 7,000Source |
| Additional Paid in CapitalUSD | 667,685,000Source | 603,093,000Source | 737,060,000Source | 664,371,000Source | 598,997,000Source | 730,448,000Source | 660,665,000Source | 593,802,000Source | 728,252,000Source | 607,229,000Source | 542,805,000Source | 522,945,000Source |
| Retained Earnings (Accumulated Deficit)USD | -584,833,000Source | -490,575,000Source | -667,673,000Source | -564,558,000Source | -464,941,000Source | -624,280,000Source | -541,275,000Source | -435,510,000Source | -605,008,000Source | -514,411,000Source | -403,282,000Source | -279,198,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 76,000Source | — | -1,000Source | -67,000Source | — | -10,000Source | -120,000Source | 0Source | 28,000Source | -106,000Source | -378,000Source |
| Stockholders' Equity Attributable to ParentUSD | 82,868,000Source | 112,602,000Source | 69,409,000Source | 99,828,000Source | 133,997,000Source | 106,189,000Source | 119,396,000Source | 158,180,000Source | 123,265,000Source | 92,854,000Source | 139,424,000Source | 243,376,000Source |
| Liabilities and EquityUSD | 104,980,000Source | 140,582,000Source | 93,540,000Source | 122,151,000Source | 163,185,000Source | 135,070,000Source | 143,952,000Source | 184,899,000Source | 146,921,000Source | 119,940,000Source | 170,515,000Source | 278,945,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,210,000Source | 16,177,000Source | 19,021,000Source | 12,654,000Source | 16,712,000Source | 16,781,000Source | 14,152,000Source | 19,158,000Source | 15,436,000Source | 15,975,000Source | 22,733,000Source | 24,248,000Source |
| Operating Lease, Liability, CurrentUSD | 2,926,000Source | 3,011,000Source | 2,879,000Source | 2,834,000Source | 3,363,000Source | 3,115,000Source | 2,794,000Source | 4,064,000Source | 3,020,000Source | 2,778,000Source | 4,319,000Source | 4,006,000Source |
| Accounts Payable, CurrentUSD | 2,843,000Source | 5,839,000Source | 2,902,000Source | 3,297,000Source | 4,319,000Source | 1,914,000Source | 5,064,000Source | 6,659,000Source | 3,581,000Source | 5,162,000Source | 5,630,000Source | 9,578,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,601,000Source | 11,527,000Source | 1,070,000Source | 9,376,000Source | 12,210,000Source | 7,002,000Source | 10,117,000Source | 7,302,000Source | 7,810,000Source | 10,830,000Source | 8,105,000Source | 11,093,000Source |
| Other Liabilities, NoncurrentUSD | 301,000Source | 276,000Source | 103,000Source | 293,000Source | 266,000Source | 418,000Source | 287,000Source | 259,000Source | 410,000Source | 281,000Source | 253,000Source | 228,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,441,000Source | 7,327,000Source | 7,514,000Source | 6,523,000Source | 9,030,000Source | 6,030,000Source | 6,294,000Source | 8,435,000Source | 8,835,000Source | 8,035,000Source | 12,784,000Source | 10,664,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 56,300,000Source | 79,500,000Source | 78,100,000Source | 71,700,000Source | 99,300,000Source | 80,900,000Source | 88,200,000Source | 122,200,000Source | 100,500,000Source | 61,400,000Source | 104,600,000Source | 204,200,000Source |
| Short-term InvestmentsUSD | — | 71,238,000Source | — | 8,996,000Source | 41,169,000Source | — | 34,386,000Source | 62,946,000Source | — | 57,123,000Source | 58,961,000Source | 91,255,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -19,272,000Source | -26,864,000Source | -90,597,000Source | -111,129,000Source | -124,084,000Source | -123,665,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 1,763,000Source | 2,661,000Source | 8,436,000Source | 8,468,000Source | 8,687,000Source | 6,467,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,196,000Source | 3,731,000Source | 13,046,000Source | 16,501,000Source | 15,309,000Source | 11,467,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,460,000Source | -379,000Source | -1,430,000Source | -581,000Source | -3,282,000Source | 1,660,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -19,234,000Source | -23,112,000Source | -68,264,000Source | -90,501,000Source | -102,072,000Source | -104,424,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -11,000Source | 22,302,000Source | 56,083,000Source | 1,131,000Source | 48,715,000Source | 83,652,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | -17,000Source | 25,000Source | -8,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 11,000Source | 383,000Source | 618,000Source | 1,025,000Source | 1,239,000Source | 20,630,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -415,000Source | 50,259,000Source | 108,405,000Source | 47,749,000Source | 4,049,000Source | 77,767,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -19,660,000Source | 49,449,000Source | 96,224,000Source | -41,621,000Source | -49,308,000Source | 56,995,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 56,731,000Source | 8,650,000Source | 78,504,000Source | 63,090,000Source | 81,306,000Source | 54,191,000Source | 100,966,000Source | 4,742,000Source | 46,363,000Source | 95,671,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,934,000Source | 3,907,000Source | 1,701,000Source | — | 2,196,000Source | 3,731,000Source | 13,046,000Source | 16,502,000Source | 15,309,000Source | 11,467,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 56,300,000Source | 79,500,000Source | 78,100,000Source | 71,700,000Source | 80,900,000Source | 88,200,000Source | 100,500,000Source | 61,400,000Source | 104,600,000Source | 204,200,000Source |
| General and Administrative ExpenseUSD | — | — | 5,573,000Source | 6,361,000Source | 5,406,000Source | 6,712,000Source | 5,447,000Source | 6,462,000Source | 24,724,000Source | 29,206,000Source | 33,155,000Source | 31,084,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 658,000Source | 1,080,000Source | 697,000Source | 815,000Source | 793,000Source | 635,000Source | 2,682,000Source | 4,737,000Source | 7,056,000Source | 1,954,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,275,000Source | -25,634,000Source | -43,393,000Source | -23,283,000Source | -19,272,000Source | -26,864,000Source | -90,597,000Source | -111,129,000Source | -124,084,000Source | -123,665,000Source |
| Nonoperating Income (Expense)USD | — | — | 661,000Source | 1,077,000Source | 695,000Source | 799,000Source | 793,000Source | 674,000Source | 2,734,000Source | 4,819,000Source | 7,109,000Source | 1,956,000Source |
| Operating ExpensesUSD | — | — | 20,936,000Source | 26,711,000Source | 45,198,000Source | 24,082,000Source | 20,290,000Source | 27,538,000Source | 93,331,000Source | 115,948,000Source | 131,193,000Source | 125,621,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 3,000Source | -3,000Source | -2,000Source | -16,000Source | — | 39,000Source | 52,000Source | 82,000Source | 53,000Source | 2,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 3,868,000Source | — |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Gain (Loss) on Termination of Lease | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -20,936,000Source | -26,711,000Source | -44,088,000Source | -24,082,000Source | -20,065,000Source | -27,538,000Source | -93,331,000Source | -115,948,000Source | -131,193,000Source | -125,621,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 3,000Source | -3,000Source | -2,000Source | -16,000Source | — | 39,000Source | 52,000Source | 82,000Source | 53,000Source | 2,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -20,275,000Source | -25,634,000Source | -43,393,000Source | -23,283,000Source | -19,272,000Source | -26,864,000Source | -90,597,000Source | -111,129,000Source | -124,084,000Source | -123,665,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,275,000Source | -25,634,000Source | -43,393,000Source | -23,283,000Source | -19,272,000Source | -26,864,000Source | -90,597,000Source | -111,129,000Source | -124,084,000Source | -123,665,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.12Source | -0.3Source | -0.2Source | -0.14Source | -0.09Source | -0.24Source | -0.59Source | -1.31Source | -1.68Source | -2.76Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.12Source | -0.3Source | -0.2Source | -0.14Source | -0.09Source | -0.24Source | -0.59Source | -1.31Source | -1.68Source | -2.76Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 163,345,972Source | 86,162,841Source | 217,574,637Source | 162,791,579Source | 216,883,164Source | 109,869,278Source | 152,971,259Source | 84,822,468Source | 73,786,126Source | 44,823,597Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 163,345,972Source | 86,162,841Source | 217,574,637Source | 162,791,579Source | 216,883,164Source | 109,869,278Source | 152,971,259Source | 84,822,468Source | 73,786,126Source | 44,823,597Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 1,900,000Source | 2,100,000Source | 1,700,000Source | 2,100,000Source | 1,800,000Source | 2,700,000Source | 8,400,000Source | 8,500,000Source | 8,700,000Source | 6,500,000Source |
| General and Administrative ExpenseUSD | — | — | 5,573,000Source | 6,361,000Source | 5,406,000Source | 6,712,000Source | 5,447,000Source | 6,462,000Source | 24,724,000Source | 29,206,000Source | 33,155,000Source | 31,084,000Source |
| Investment Income, InterestUSD | — | — | 658,000Source | 1,080,000Source | 697,000Source | 815,000Source | 793,000Source | 635,000Source | 2,682,000Source | 4,737,000Source | 7,056,000Source | 1,954,000Source |
| Nonoperating Income (Expense)USD | — | — | 661,000Source | 1,077,000Source | 695,000Source | 799,000Source | 793,000Source | 674,000Source | 2,734,000Source | 4,819,000Source | 7,109,000Source | 1,956,000Source |
| Operating ExpensesUSD | — | — | 20,936,000Source | 26,711,000Source | 45,198,000Source | 24,082,000Source | 20,290,000Source | 27,538,000Source | 93,331,000Source | 115,948,000Source | 131,193,000Source | 125,621,000Source |
| Research and Development ExpenseUSD | — | — | 15,363,000Source | 20,350,000Source | 16,603,000Source | 17,370,000Source | 14,843,000Source | 21,076,000Source | 68,607,000Source | 86,742,000Source | 98,038,000Source | 94,537,000Source |
| Total Revenue | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
tnya-ex4_2.htm · S-8 · 2026-08-05
Exhibit 4.2 AMENDED AND RESTATED TENAYA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN (as amended and restated) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appre…
Read attachment ↗tnya-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2…
Read attachment ↗tnya-ex99_1.htm · 8-K · 2026-06-29
EX-99.1 3 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise SOUTH SAN FRANCISCO, Calif., June 29, 2026 - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announ…
Read attachment ↗tnya-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM Expected in the Second Quarter 2026 Preclinical Data at MDA 2026 Highlighted TN-301’s Ac…
Read attachment ↗